Uses of fgf21 fusion proteins

A method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of an FGF21 fusion protein at least once every four weeks,

• wherein the therapeutically effective amount of the FGF21 fusion protein is 5 mg or more,
• wherein the FGF21 fusion protein comprises, from the N-terminus to C-terminus, a human fibroblast growth factor 21 or an analog thereof, a flexible peptide linker, at least one rigid unit comprising a carboxyl terminal peptide of human chorionic gonadotropin β subunit, and a fusion partner selected from an immunoglobulin, an Fc fragment thereof, an albumin, and transferrin, and
• wherein the disease or disorder is selected from non-alcoholic fatty liver disease (NAFLD), diabetes, diabetic complications, obesity, dyslipidemia, metabolic syndrome, and disorders associated with severe inactivating mutations in the insulin receptor.